Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 27
Filter
1.
Int J Mol Sci ; 23(3)2022 Jan 21.
Article in English | MEDLINE | ID: mdl-35163106

ABSTRACT

We used α-Latrotoxin (α-LTx), the main neurotoxic component of the black widow spider venom, which causes degeneration of the neuromuscular junction (NMJ) followed by a rapid and complete regeneration, as a molecular tool to identify by RNA transcriptomics factors contributing to the structural and functional recovery of the NMJ. We found that Urocortin 2 (UCN2), a neuropeptide involved in the stress response, is rapidly expressed at the NMJ after acute damage and that inhibition of CRHR2, the specific receptor of UCN2, delays neuromuscular transmission rescue. Experiments in neuronal cultures show that CRHR2 localises at the axonal tips of growing spinal motor neurons and that its expression inversely correlates with synaptic maturation. Moreover, exogenous UCN2 enhances the growth of axonal sprouts in cultured neurons in a CRHR2-dependent manner, pointing to a role of the UCN2-CRHR2 axis in the regulation of axonal growth and synaptogenesis. Consistently, exogenous administration of UCN2 strongly accelerates the regrowth of motor axon terminals degenerated by α-LTx, thereby contributing to the functional recovery of neuromuscular transmission after damage. Taken together, our results posit a novel role for UCN2 and CRHR2 as a signalling axis involved in NMJ regeneration.


Subject(s)
Axons/physiology , Motor Neurons/cytology , Nerve Regeneration , Neuromuscular Junction Diseases/prevention & control , Neuromuscular Junction/pathology , Spider Venoms/toxicity , Urocortins/metabolism , Animals , Female , Mice , Mice, Inbred C57BL , Neuromuscular Junction/drug effects , Neuromuscular Junction Diseases/chemically induced , Neuromuscular Junction Diseases/metabolism , Neuromuscular Junction Diseases/pathology , Presynaptic Terminals , Rats , Rats, Sprague-Dawley , Urocortins/genetics
2.
Biomolecules ; 11(8)2021 07 28.
Article in English | MEDLINE | ID: mdl-34439778

ABSTRACT

Neuro-muscular disorders include a variety of diseases induced by genetic mutations resulting in muscle weakness and waste, swallowing and breathing difficulties. However, muscle alterations and nerve depletions involve specific molecular and cellular mechanisms which lead to the loss of motor-nerve or skeletal-muscle function, often due to an excessive cell death. Morphological and molecular studies demonstrated that a high number of these disorders seem characterized by an upregulated apoptosis which significantly contributes to the pathology. Cell death involvement is the consequence of some cellular processes that occur during diseases, including mitochondrial dysfunction, protein aggregation, free radical generation, excitotoxicity and inflammation. The latter represents an important mediator of disease progression, which, in the central nervous system, is known as neuroinflammation, characterized by reactive microglia and astroglia, as well the infiltration of peripheral monocytes and lymphocytes. Some of the mechanisms underlying inflammation have been linked to reactive oxygen species accumulation, which trigger mitochondrial genomic and respiratory chain instability, autophagy impairment and finally neuron or muscle cell death. This review discusses the main inflammatory pathways contributing to cell death in neuro-muscular disorders by highlighting the main mechanisms, the knowledge of which appears essential in developing therapeutic strategies to prevent the consequent neuron loss and muscle wasting.


Subject(s)
Apoptosis/genetics , Hereditary Sensory and Motor Neuropathy/metabolism , Motor Neuron Disease/metabolism , Muscular Diseases/metabolism , Muscular Dystrophies/metabolism , Neuromuscular Junction Diseases/metabolism , Astrocytes/metabolism , Astrocytes/pathology , Autophagy/genetics , Cytokines/genetics , Cytokines/metabolism , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Gene Expression Regulation , Hereditary Sensory and Motor Neuropathy/genetics , Hereditary Sensory and Motor Neuropathy/pathology , Humans , Inflammation , Microglia/metabolism , Microglia/pathology , Mitochondria/metabolism , Mitochondria/pathology , Motor Neuron Disease/genetics , Motor Neuron Disease/pathology , Muscular Diseases/genetics , Muscular Diseases/pathology , Muscular Dystrophies/genetics , Muscular Dystrophies/pathology , NF-kappa B/genetics , NF-kappa B/metabolism , Neuromuscular Junction Diseases/genetics , Neuromuscular Junction Diseases/pathology , Neurons/metabolism , Neurons/pathology , Signal Transduction
3.
Neurosci Lett ; 716: 134676, 2020 01 18.
Article in English | MEDLINE | ID: mdl-31811897

ABSTRACT

The receptor tyrosine kinase MuSK (muscle-specific kinase) is the key signaling molecule during the formation of a mature and functional neuromuscular junction (NMJ). Signal transduction events downstream of MuSK activation induce both pre- and postsynaptic differentiation, which, most prominently, includes the clustering of acetylcholine receptors (AChRs) at synaptic sites. MuSK activation requires a complex interplay between its co-receptor Lrp4 (low-density lipoprotein receptor-related protein-4), the motor neuron-derived heparan-sulfate proteoglycan Agrin and the intracellular adaptor protein Dok-7. A tight regulation of MuSK kinase activity is crucial for proper NMJ development. Defects in MuSK signaling are the cause of muscle weakness as reported in congenital myasthenic syndromes and myasthenia gravis. This review focuses on recent structure-based analyses of MuSK, Agrin, Lrp4 and Dok-7 interactions and their function during MuSK activation. Conclusions about the regulation of the MuSK kinase that were derived from molecular structures will be highlighted. In addition, the role of MuSK during development and disease will be discussed.


Subject(s)
Neuromuscular Junction Diseases/metabolism , Neuromuscular Junction/metabolism , Receptor Protein-Tyrosine Kinases/metabolism , Receptors, Cholinergic/metabolism , Agrin/metabolism , Animals , Humans , LDL-Receptor Related Proteins/metabolism , Muscle Proteins/metabolism
4.
Int J Mol Sci ; 18(4)2017 Apr 24.
Article in English | MEDLINE | ID: mdl-28441759

ABSTRACT

In the neuromuscular junction, postsynaptic nicotinic acetylcholine receptor (nAChR) clustering, trans-synaptic communication and synaptic stabilization are modulated by the molecular mechanisms underlying synaptic plasticity. The synaptic functions are based presynaptically on the active zone architecture, synaptic vesicle proteins, Ca2+ channels and synaptic vesicle recycling. Postsynaptically, they are based on rapsyn-anchored nAChR clusters, localized sensitivity to ACh, and synaptic stabilization via linkage to the extracellular matrix so as to be precisely opposed to the nerve terminal. Focusing on neural agrin, Wnts, muscle-specific tyrosine kinase (a mediator of agrin and Wnts signalings and regulator of trans-synaptic communication), low-density lipoprotein receptor-related protein 4 (the receptor of agrin and Wnts and participant in retrograde signaling), laminin-network (including muscle-derived agrin), extracellular matrix proteins (participating in the synaptic stabilization) and presynaptic receptors (including muscarinic and adenosine receptors), we review the functional structures of the synapse by making reference to immunological pathogenecities in postsynaptic disease, myasthenia gravis. The synapse-related proteins including cortactin, coronin-6, caveolin-3, doublecortin, R-spondin 2, amyloid precursor family proteins, glia cell-derived neurotrophic factor and neurexins are also discussed in terms of their possible contribution to efficient synaptic transmission at the neuromuscular junction.


Subject(s)
Neuromuscular Junction Diseases/pathology , Animals , Humans , LDL-Receptor Related Proteins/metabolism , Neuromuscular Junction Diseases/immunology , Neuromuscular Junction Diseases/metabolism , Receptors, Muscarinic/metabolism , Receptors, Nicotinic/metabolism , Receptors, Purinergic P1/metabolism , Synapses/metabolism
5.
J Gerontol A Biol Sci Med Sci ; 72(5): 640-648, 2017 May 01.
Article in English | MEDLINE | ID: mdl-27382038

ABSTRACT

The loss of muscle strength with age has been studied from the perspective of a decline in muscle mass and neuromuscular junction (NMJ) stability. A third potential factor is force transmission. The purpose of this study was to determine the changes in the force transfer apparatus within aging muscle and the impact on membrane integrity and NMJ stability. We measured an age-related loss of dystrophin protein that was greatest in the flexor muscles. The loss of dystrophin protein occurred despite a twofold increase in dystrophin mRNA. Importantly, this disparity could be explained by the four- to fivefold upregulation of the dystromir miR-31. To compensate for the loss of dystrophin protein, aged muscle contained increased α-sarcoglycan, syntrophin, sarcospan, laminin, ß1-integrin, desmuslin, and the Z-line proteins α-actinin and desmin. In spite of the adaptive increase in other force transfer proteins, over the 48 hours following lengthening contractions, the old muscles showed more signs of impaired membrane integrity (fourfold increase in immunoglobulin G-positive fibers and 70% greater dysferlin mRNA) and NMJ instability (14- to 96-fold increases in Runx1, AchRδ, and myogenin mRNA). Overall, these data suggest that age-dependent alterations in dystrophin leave the muscle membrane and NMJ more susceptible to contraction-induced damage even before changes in muscle mass are obvious.


Subject(s)
Aging/metabolism , Dystrophin/metabolism , Muscle, Skeletal/metabolism , Neuromuscular Junction Diseases/metabolism , Neuromuscular Junction/metabolism , Animals , Blotting, Western , Electric Stimulation , Immunohistochemistry , Muscle Contraction , Muscle Proteins/metabolism , RNA/analysis , Rats , Rats, Inbred F344
6.
Scand J Med Sci Sports ; 25 Suppl 2: 33-9, 2015 Aug.
Article in English | MEDLINE | ID: mdl-26083700

ABSTRACT

This study investigated features of skeletal muscle ageing in elderly individuals having previously undergone unilateral total knee arthroplasty (TKA) and whether markers of sarcopenia could be mitigated by a 12-week alpine skiing intervention. Novel biomarkers agrin, indicative of neuromuscular junction (NMJ) degeneration, tumor suppressor protein p53, associated with muscle atrophy, and a new ultrasound-based muscle architecture biomarker were used to characterize sarcopenia. Participant details and study design are presented by Kösters et al. (2015). The results of this study show that NMJ degeneration is widespread among active septuagenarians previously subjected to TKA: all participants showed elevated agrin levels upon recruitment. At least 50% of individuals were identified as sarcopenic based on their muscle architecture, supporting the hypothesis that NMJ alterations precede sarcopenia. Notably, sarcopenia was strongly associated with the expression of p53, which seems to confirm its validity as a biomarker of muscle atrophy. Training did not significantly modify any of these biomarkers. In view of the lack of accretion of muscle mass in response to the alpine skiing intervention, we hypothesize that local muscle inflammation and oxidative stress may have blunted the anabolic response to training and promoted muscle breakdown in this elderly post-TKA population.


Subject(s)
Aging/metabolism , Agrin/metabolism , Arthroplasty, Replacement, Knee , Osteoarthritis, Knee/surgery , Quadriceps Muscle/metabolism , Sarcopenia/metabolism , Skiing , Tumor Suppressor Protein p53/metabolism , Aged , Female , Humans , Male , Middle Aged , Muscle, Skeletal/diagnostic imaging , Muscle, Skeletal/metabolism , Muscular Atrophy/metabolism , Neuromuscular Junction Diseases/metabolism , Quadriceps Muscle/diagnostic imaging , Sarcopenia/diagnostic imaging , Ultrasonography
7.
Curr Opin Pharmacol ; 12(3): 340-6, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22365504

ABSTRACT

The neuromuscular junction (NMJ) is a specialized synapse between motor neurons and skeletal muscle with a complex signaling network that assures highly reliable neuromuscular transmission. Diseases of the NMJ cause skeletal muscle fatigue and include inherited and acquired disorders that affect presynaptic, intrasynaptic or postsynaptic components. Moreover, fragmentation of the NMJ contributes to sarcopenia, the loss of muscle mass during aging. Studies from recent years indicate that the formation and stabilization of NMJs differs between various muscles and that this difference affects their response under pathological conditions. This review summarizes the most important mechanisms involved in the development, maintenance and dysfunction of the NMJ and it discusses their significance in myasthenic disorders and aging and as targets for possible future treatment of NMJ dysfunction.


Subject(s)
Aging/metabolism , Neuromuscular Junction Diseases/metabolism , Neuromuscular Junction/metabolism , Signal Transduction , Adrenergic beta-2 Receptor Agonists/adverse effects , Adrenergic beta-2 Receptor Agonists/pharmacology , Adrenergic beta-2 Receptor Agonists/therapeutic use , Adult , Animals , Child , Humans , Muscle Development , Neurogenesis , Neuromuscular Junction/drug effects , Neuromuscular Junction/growth & development , Neuromuscular Junction/physiopathology , Neuromuscular Junction Diseases/drug therapy , Neuromuscular Junction Diseases/immunology , Neuromuscular Junction Diseases/physiopathology , Receptors, Cholinergic/metabolism , Sarcopenia/drug therapy , Sarcopenia/metabolism , Sarcopenia/physiopathology , Signal Transduction/drug effects
8.
J Neuropathol Exp Neurol ; 70(6): 444-61, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21572339

ABSTRACT

A detailed pathologic analysis was performed on Smn(-/-);SMN2 mice as a mouse model for human type I spinal muscular atrophy (SMA). We provide new data concerning changes in the spinal cord, neuromuscular junctions and muscle cells, and in the organs of the immune system. The expression of 10 synaptic proteins was analyzed in 3-dimensionally reconstructed neuromuscular junctions by confocal microscopy. In addition to defects in postsynaptic occupancy, there was a marked reduction in calcitonin gene-related peptide and Rab3A in the presynaptic motor terminals of some, but not all, of the skeletal muscles analyzed. Defects in the organization of presynaptic nerve terminals were also detected by electron microscopy. Moreover, degenerative changes in muscle cells, defective postnatal muscle growth, and prominent muscle satellite cell apoptosis were also observed. All of these changes occurred in the absence of massive loss of spinal cord motoneurons. On the other hand, astroglia, but not microglia, increased in the ventral horn of newborn SMA mice. In skeletal muscles, the density of interstitial macrophages was significantly reduced, and monocyte chemotactic protein-1 was downregulated. These findings raise questions regarding the primary contribution of a muscle cell defect to the SMA phenotype.


Subject(s)
Muscle Development/physiology , Muscular Atrophy, Spinal/pathology , Neuromuscular Junction Diseases/pathology , Neuromuscular Junction/pathology , Animals , Animals, Newborn , Apoptosis/genetics , Calcitonin Gene-Related Peptide/metabolism , Disease Models, Animal , Down-Regulation/genetics , Embryo, Mammalian , Humans , In Situ Nick-End Labeling/methods , Mice , Mice, Transgenic , Muscle Development/genetics , Muscle, Skeletal/pathology , Muscle, Skeletal/ultrastructure , Muscular Atrophy, Spinal/complications , Muscular Atrophy, Spinal/genetics , Muscular Atrophy, Spinal/mortality , Neuromuscular Junction/genetics , Neuromuscular Junction/growth & development , Neuromuscular Junction/ultrastructure , Neuromuscular Junction Diseases/etiology , Neuromuscular Junction Diseases/metabolism , Survival of Motor Neuron 1 Protein/genetics , Survival of Motor Neuron 2 Protein/genetics , rab3 GTP-Binding Proteins/metabolism
9.
Neurosci Lett ; 487(3): 350-3, 2011 Jan 10.
Article in English | MEDLINE | ID: mdl-21029764

ABSTRACT

This work was undertaken in order to study the possible role of alpha-synuclein in the function of the neuro-muscular junction in skeletal muscles. Repeated stimulation of skeletal muscle motor neurons revealed signs of neuromuscular pathology in alpha-synuclein null mutated (C57Bl/6JOlaHsd) and knockout (B6;129X1-Snca(tm1Rosl)/J) mice. This stimulation produced repetitive compound muscle action potentials in both lines of alpha-synuclein deficient mice. Muscle strength and muscle coordination during ambulation were unaffected, though motor learning was slower in alpha-synuclein deficient mice in the Rotarod test. We conclude that alpha-synuclein may play a role in acetylcholine compartmentalization at the neuromuscular junction, and in the fine control of activity of skeletal muscles.


Subject(s)
Motor Activity/physiology , Muscle, Skeletal/pathology , Neuromuscular Junction Diseases/pathology , alpha-Synuclein/metabolism , Action Potentials/physiology , Animals , Electromyography , Mice , Mice, Inbred C57BL , Mice, Knockout , Muscle, Skeletal/metabolism , Neuromuscular Junction Diseases/metabolism , alpha-Synuclein/deficiency
10.
J Neurosci Res ; 88(8): 1651-63, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20077429

ABSTRACT

Campylobacteriosis is a frequent antecedent event in Guillain-Barré syndrome (GBS), inducing high-titer serum antibodies for ganglioside antigens in the peripheral nervous system (PNS). Molecular mimicry between the lipooligosaccharide (LOS) component of Campylobacter jejuni and human peripheral nerve gangliosides is believed to play an important role in the pathogenesis of GBS. Conventional treatment strategies for patients with GBS include plasmapheresis, intravenous immunoglobulin (IVIG), and immunosuppression, which are invasive or relatively ineffective. In this study, we used our animal model of GBS, in which Lewis rats were immunized with GD3-like LOS isolated from C.jejuni. The animals developed anti-GD3 ganglioside antibodies and manifested neuromuscular dysfunction. To develop novel therapeutic strategies, we treated the animals by intraperitoneal administration of an anti-GD3 antiidiotype monoclonal antibody (BEC2) that specifically interacts with the pathogenic antibody. The treated animals had a remarkable reduction of anti-GD3 antibody titers and improvement of motor nerve functions. The results suggest that ganglioside mimics, such as antiidiotype antibodies, may be powerful reagents for therapeutic intervention in GBS by neutralizing specific pathogenic antiganglioside antibodies.


Subject(s)
Antibodies, Anti-Idiotypic/therapeutic use , Gangliosides/immunology , Neuritis, Autoimmune, Experimental/therapy , Action Potentials/drug effects , Action Potentials/physiology , Animals , Biotinylation/methods , Campylobacter jejuni/immunology , Coculture Techniques/methods , Disease Models, Animal , Dose-Response Relationship, Drug , Enzyme-Linked Immunosorbent Assay/methods , Ether-A-Go-Go Potassium Channels/immunology , Ether-A-Go-Go Potassium Channels/metabolism , Ether-A-Go-Go Potassium Channels/pharmacokinetics , Female , Freund's Adjuvant/immunology , Lipopolysaccharides , Motor Neurons/pathology , Motor Neurons/ultrastructure , Muscle, Skeletal/physiology , Nerve Tissue Proteins/immunology , Nerve Tissue Proteins/metabolism , Nerve Tissue Proteins/pharmacokinetics , Neuritis, Autoimmune, Experimental/chemically induced , Neuritis, Autoimmune, Experimental/complications , Neuritis, Autoimmune, Experimental/immunology , Neuromuscular Junction Diseases/drug therapy , Neuromuscular Junction Diseases/etiology , Neuromuscular Junction Diseases/metabolism , Organ Culture Techniques , Rats , Rotarod Performance Test/methods , Sciatic Nerve/pathology , Sciatic Nerve/ultrastructure , Spinal Cord/physiology , Time Factors
11.
Neurobiol Dis ; 38(1): 125-35, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20085811

ABSTRACT

Spinal muscular atrophy (SMA) is caused by insufficient levels of the survival motor neuron (SMN) protein leading to muscle paralysis and respiratory failure. In mouse, introducing the human SMN2 gene partially rescues Smn(-)(/)(-) embryonic lethality. However current models were either too severe or nearly unaffected precluding convenient drug testing for SMA. We report here new SMN2;Smn(-/-) lines carrying one to four copies of the human SMN2 gene. Mice carrying three SMN2 copies exhibited an intermediate phenotype with delayed appearance of motor defects and developmental breathing disorders reminiscent of those found in severe SMA patients. Although normal at birth, at 7 days of age respiratory rate was decreased and apnea frequency was increased in SMA mice in parallel with the appearance of neuromuscular junction defects in the diaphragm. With median survival of 15 days and postnatal onset of neurodegeneration, these mice could be an important tool for evaluating new therapeutics.


Subject(s)
Muscular Atrophy, Spinal/physiopathology , Neuromuscular Junction Diseases/physiopathology , Respiratory Paralysis/physiopathology , Animals , Diaphragm/innervation , Diaphragm/physiopathology , Disease Models, Animal , Disease Progression , Genes, Lethal/physiology , Genetic Predisposition to Disease/genetics , Humans , Mice , Mice, Transgenic , Muscular Atrophy, Spinal/genetics , Muscular Atrophy, Spinal/metabolism , Neuromuscular Junction/genetics , Neuromuscular Junction/metabolism , Neuromuscular Junction/pathology , Neuromuscular Junction Diseases/genetics , Neuromuscular Junction Diseases/metabolism , Respiratory Insufficiency/genetics , Respiratory Insufficiency/metabolism , Respiratory Insufficiency/physiopathology , Respiratory Paralysis/genetics , Respiratory Paralysis/metabolism , Survival of Motor Neuron 2 Protein/genetics
12.
Neurology ; 73(3): 228-35, 2009 Jul 21.
Article in English | MEDLINE | ID: mdl-19620612

ABSTRACT

BACKGROUND: Pathogenic mutations in rapsyn result in endplate acetylcholine receptor (AChR) deficiency and are a common cause of postsynaptic congenital myasthenic syndromes. METHODS: Clinical, electrophysiologic, pathologic, and molecular studies were done in 39 patients. RESULTS: In all but one patient, the disease presented in the first 2 years of life. In 9 patients, the myasthenic symptoms included constant or episodic ophthalmoparesis, and 1 patient had a pure limb-girdle phenotype. More than one-half of the patients experienced intermittent exacerbations. Long-term follow-up was available in 25 patients after start of cholinergic therapy: 21 became stable or were improved and 2 of these became asymptomatic; 3 had a progressive course; and 1 died in infancy. In 7 patients who had endplate studies, the average counts of AChR per endplate and the synaptic response to ACh were less reduced than in patients harboring low AChR expressor mutations. Eight patients were homozygous and 23 heterozygous for the common p.N88K mutation. Six mutations, comprising 3 missense mutations, an in-frame deletion, a splice-site mutation, and a nonsense mutation, are novel. Homozygosity for p.N88K was associated with varying grades of severity. No genotype-phenotype correlations were observed except in 8 Near-Eastern patients homozygous for the promoter mutation (c.-38A>G), who had a mild course. CONCLUSIONS: All but 1 patient presented early in life and most responded to cholinergic agonists. With early diagnosis and therapy, rapsyn deficiency has a benign course in most patients. There was no consistent phenotype-genotype correlation except for an E-box mutation associated with jaw deformities.


Subject(s)
Genetic Predisposition to Disease/genetics , Muscle Proteins/deficiency , Muscle Proteins/genetics , Myasthenic Syndromes, Congenital/genetics , Neuromuscular Junction Diseases/genetics , Receptors, Cholinergic/genetics , Adolescent , Adult , Age of Onset , Child , Child, Preschool , Cholinergic Agonists/therapeutic use , DNA Mutational Analysis , Disease Progression , Female , Genetic Testing , Genotype , Homozygote , Humans , Male , Mutation/genetics , Myasthenic Syndromes, Congenital/metabolism , Myasthenic Syndromes, Congenital/physiopathology , Neuromuscular Junction Diseases/metabolism , Neuromuscular Junction Diseases/physiopathology , Phenotype , Receptors, Cholinergic/metabolism , Young Adult
13.
Neuromuscul Disord ; 19(5): 366-78, 2009 May.
Article in English | MEDLINE | ID: mdl-19346129

ABSTRACT

Mice deficient in the glycosyltransferase Large are characterized by severe muscle and central nervous system abnormalities. In this study, we show that the formation and maintenance of neuromuscular junctions in Large(myd) mice are greatly compromised. Neuromuscular junctions are not confined to the muscle endplate zone but are widely spread and are frequently accompanied by exuberant nerve sprouting. Nerve terminals are highly fragmented and binding of alpha-bungarotoxin to postsynaptic acetylcholine receptors (AChRs) is greatly reduced. In vitro, Large(myd) myotubes are responsive to agrin but produce aberrant AChR clusters, which are larger in area and less densely packed with AChRs. In addition, AChR expression on the cell surface is diminished suggesting that AChR assembly or transport is defective. These results together with the finding that O-linked glycosylation at neuromuscular junctions of Large(myd) mice is compromised indicate that the action of Large is necessary for proper neuromuscular junction development.


Subject(s)
Genetic Predisposition to Disease/genetics , N-Acetylglucosaminyltransferases/genetics , Neuromuscular Junction Diseases/genetics , Neuromuscular Junction Diseases/metabolism , Neuromuscular Junction/genetics , Neuromuscular Junction/metabolism , Agrin/metabolism , Animals , Disease Models, Animal , Mice , Mice, Inbred C57BL , Mice, Inbred mdx , Mice, Mutant Strains , Muscle Fibers, Skeletal/metabolism , Muscle Fibers, Skeletal/pathology , Muscle, Skeletal/innervation , Muscle, Skeletal/metabolism , Muscle, Skeletal/physiopathology , Mutation/genetics , Neuromuscular Junction/physiopathology , Neuromuscular Junction Diseases/physiopathology , Presynaptic Terminals/metabolism , Presynaptic Terminals/pathology , Receptors, Nicotinic/metabolism , Synaptic Membranes/metabolism , Synaptic Membranes/pathology
14.
J Neurosci ; 28(49): 13223-31, 2008 Dec 03.
Article in English | MEDLINE | ID: mdl-19052214

ABSTRACT

The contraction of skeletal muscle is dependent on synaptic transmission through acetylcholine receptors (AChRs) at the neuromuscular junction (NMJ). The lack of an AChR subunit causes a fetal akinesia in humans, leading to death in the first trimester and characteristic features of Fetal Akinesia Deformation Sequences (FADS). A corresponding null mutation of the delta-subunit in zebrafish (sofa potato; sop) leads to the death of embryos around 5 d postfertilization (dpf). In sop(-/-) mutants, we expressed modified delta-subunits, with one (delta1YFP) or two yellow fluorescent protein (delta2YFP) molecules fused at the intracellular loop, under the control of an alpha-actin promoter. AChRs containing these fusion proteins are fluorescent, assemble on the plasma membrane, make clusters under motor neuron endings, and generate synaptic current. We screened for germ-line transmission of the transgene and established a line of sop(-/-) fish stably expressing the delta2YFP. These delta2YFP/sop(-/-) embryos can mount escape behavior close to that of their wild-type siblings. Synaptic currents in these embryos had a smaller amplitude, slower rise time, and slower decay when compared with wild-type fish. Remarkably, these embryos grow to adulthood and display complex behaviors such as feeding and breeding. To the best of our knowledge, this is the first case of a mutant animal corresponding to first trimester lethality in human that has been rescued by a transgene and survived to adulthood. In the rescued fish, a foreign promoter drove the transgene expression and the NMJ had altered synaptic strength. The survival of the transgenic animal delineates requirements for gene therapies of NMJ.


Subject(s)
Longevity/genetics , Mutation/genetics , Neuromuscular Junction Diseases/genetics , Receptors, Cholinergic/genetics , Zebrafish/growth & development , Zebrafish/genetics , Acetylcholine/metabolism , Animals , Animals, Genetically Modified , Feeding Behavior/physiology , Female , Gene Expression Regulation, Developmental/genetics , Luminescent Proteins/genetics , Male , Neuromuscular Junction/genetics , Neuromuscular Junction/metabolism , Neuromuscular Junction/physiopathology , Neuromuscular Junction Diseases/metabolism , Neuromuscular Junction Diseases/physiopathology , Protein Subunits/chemistry , Protein Subunits/genetics , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics , Sexual Behavior, Animal/physiology , Sexual Maturation/genetics , Synaptic Membranes/genetics , Synaptic Membranes/metabolism , Synaptic Membranes/ultrastructure , Synaptic Transmission/genetics , Transgenes/genetics , Zebrafish/metabolism
16.
Neuroscience ; 148(1): 1-6, 2007 Aug 10.
Article in English | MEDLINE | ID: mdl-17640821

ABSTRACT

Rab3a is a small GTP binding protein associated with presynaptic vesicles that is thought to regulate vesicle targeting to active zones. Although this rab3a function implies that vesicle docking and action potential-evoked release might be inhibited in rab3a gene-deleted synapses, such inhibition has never been demonstrated. To investigate vesicle docking at the neuromuscular junction of rab3a gene-deleted (rab3a(-)) mice, we performed electron microscopy analysis of the diaphragm slow-fatigue (type I) synapses. We found a significant (26%) reduction in the number of vesicles docked to the presynaptic membrane in rab3a(-) terminals, although intraterminal vesicles were not affected. Aiming to detect possible changes in quantal release due to rab3a gene deletion, we minimized the variability between preparations employing focal recordings of synaptic responses from visualized type I endplates. We found a significant decrease in both evoked (27% reduction in quantal content) and spontaneous (28% reduction in mini frequency) quantal release. The decrease in the evoked release produced by rab3a deletion was most pronounced at reduced extracellular Ca(2+) concentrations (over 50% decrease at 0.5 and 0.2 mM Ca(2+)). By manipulating extracellular calcium, we demonstrated that calcium cooperativity is not altered in rab3a(-) synapses, however calcium sensitivity of quantal release is affected. Thus, we demonstrated that rab3a positively regulates docking and basal quantal release at the mouse neuromuscular junction. This result is consistent with the proposed role of rab3a in trafficking and targeting vesicles to the active zones.


Subject(s)
Diaphragm/innervation , Neuromuscular Junction/metabolism , Neurotransmitter Agents/metabolism , Synaptic Transmission/genetics , Synaptic Vesicles/metabolism , rab3A GTP-Binding Protein/genetics , Animals , Calcium/deficiency , Calcium Signaling/genetics , Diaphragm/physiopathology , Excitatory Postsynaptic Potentials/genetics , Exocytosis/genetics , Mice , Mice, Knockout , Microscopy, Electron, Transmission , Motor Neurons/metabolism , Motor Neurons/ultrastructure , Neuromuscular Junction/ultrastructure , Neuromuscular Junction Diseases/genetics , Neuromuscular Junction Diseases/metabolism , Neuromuscular Junction Diseases/physiopathology , Presynaptic Terminals/metabolism , Presynaptic Terminals/ultrastructure , Synaptic Membranes/metabolism , Synaptic Membranes/ultrastructure , Synaptic Vesicles/ultrastructure
17.
J Orthop Res ; 25(11): 1498-505, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17568415

ABSTRACT

Neuromuscular junction destabilization following nerve injury contributes to irreversible functional impairment. Myogenic Regulatory Factors (MRF's) including myoblast determination factor (MyoD), MRF-4, Myogenin, and myogenic factors-5 (myf-5), and Growth-associated protein 43 KDa (GAP43) regulate gene expression of nicotinic acetylcholine receptor (nAChR) subunits (alpha, beta, delta, gamma, and epsilon). We hypothesized that nerve injury induces altered gene expression of MRF's, nAChRs, and GAP-43 in the skeletal muscle which destabilize neuromuscular junctions. The tibial nerve was transected in 42 juvenile male Sprague-Dawley rats. Denervated and contralateral control gastrocnemius m. mRNA for nAChR subunits, MRF's, and GAP-43 were determined by real time reverse transcription polymerase chain reaction (real time RT-PCR). After transection, muscle mass decreased for 1 year with a nadir of 75% at 3 months. Alpha, gamma, and epsilon subunit genes increased by 3 and peaked at 7 days before returning to control levels (P < 0.05). Beta subunits and GAP-43 tended to increase. Delta subunits peaked at 3 days returning to control levels by 30 days. By one month, most of the nAChR subunits had returned to control levels. Alpha, beta, gamma, and delta subunit expression remained significantly lower than control up to 1 year later (P < 0.05). MRF4, Myogenin, and MyoD expression paralleled that of alpha, gamma, and epsilon nAChR subunits (P < 0.05). Gene expression of nAChR alpha, gamma, delta and epsilon subunits was biphasic in the first month after nerve injury, similar to that of MRF's. nAChR subunits and MRF's may play a critical role in neuromuscular junction stability.


Subject(s)
GAP-43 Protein/biosynthesis , Gene Expression Regulation , Muscle, Skeletal/metabolism , Myogenic Regulatory Factors/biosynthesis , Neuromuscular Junction Diseases/metabolism , Receptors, Nicotinic/biosynthesis , Animals , Disease Models, Animal , GAP-43 Protein/genetics , Gene Expression Profiling , Male , Muscle Denervation , Muscle, Skeletal/innervation , Muscle, Skeletal/physiopathology , Myogenic Regulatory Factors/genetics , Neuromuscular Junction Diseases/genetics , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Receptors, Nicotinic/genetics , Reverse Transcriptase Polymerase Chain Reaction , Sciatic Nerve/injuries
18.
Hum Exp Toxicol ; 25(7): 353-9, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16898163

ABSTRACT

Occupationally-exposed lead affects the neuromuscular junction and might cause disturbances in the locomotor activity. This study was undertaken to evaluate pteridine metabolism, in which neurotransmitters are synthesized in battery workers. Urinary neopterin, biopterin and creatinine were measured using high performance liquid chromatography. Serum neopterin concentrations were detected by enzyme-linked immunoassay. Blood dihydropteridine reductase (DHPR) activities and deltaaminolevulinic acid (delta-ALA) were measured spectrophotometrically. Blood and urinary lead were detected by atomic absorption spectroscopy. Significantly increased blood and urinary lead levels, urinary neopterin, biopterin and delta-ALA were found in workers, while DHPR activities were indifferent compared to control group. Urinary creatinine decreased. This is the first study to demonstrate that increased activity of the pteridine pathway results in the accumulation of the neurotransmitters that may be responsible for the neurological disorders.


Subject(s)
Air Pollutants, Occupational/toxicity , Biopterins/urine , Lead/toxicity , Occupational Exposure , Pteridines/metabolism , Adult , Air Pollutants, Occupational/blood , Air Pollutants, Occupational/urine , Aminolevulinic Acid/blood , Biomarkers/blood , Biomarkers/urine , Biopterins/metabolism , Creatinine/urine , Dihydropteridine Reductase/blood , Dihydropteridine Reductase/metabolism , Environmental Monitoring/methods , Evaluation Studies as Topic , Humans , Lead/blood , Lead/urine , Male , Neopterin/blood , Neopterin/metabolism , Neopterin/urine , Neuromuscular Junction Diseases/blood , Neuromuscular Junction Diseases/metabolism , Neuromuscular Junction Diseases/urine , Pteridines/blood , Pteridines/urine
19.
Glia ; 53(1): 13-23, 2006 Jan 01.
Article in English | MEDLINE | ID: mdl-16078241

ABSTRACT

In addition to their role in action potential generation and fast synaptic transmission in neurons, voltage-dependent sodium channels can also be active in glia. Terminal Schwann cells (TSCs) wrap around the nerve terminal arborization at the neuromuscular junction, which they contribute to shape during development and in the postdenervation processes. Using fluorescent in situ hybridization (FISH), immunofluorescence, and confocal microscopy, we detected the neuronal Nav1.6 sodium channel transcripts and proteins in TSCs in normal adult rats and mice. Nav1.6 protein co-localized with the Schwann cell marker S-100 but was not detected in the SV2-positive nerve terminals. The med phenotype in mice is due to a mutation in the SCN8A gene resulting in loss of Nav1.6 expression. It leads to early onset in postnatal life of defects in neuromuscular transmission with minimal alteration of axonal conduction. Strikingly, in mutant mice, the nonmyelinated pre-terminal region of axons showed abundant sprouting at neuromuscular junctions, and most of the alpha-bungarotoxin-labeled endplates were devoid of S-100- or GFAP-positive TSCs. Using specific antibodies against the Nav1.2 and Nav1.6 sodium channels, ankyrin G and Caspr 1, and a pan sodium channel antibody, we found that a similar proportion of ankyrin G-positive nodes of Ranvier express sodium channels in mutant and wild-type animals and that nodal expression of Nav1.2 persists in med mice. Our data supports the hypothesis that the lack of expression of Nav1.6 in Schwann cells at neuromuscular junctions might play a role in the med phenotype.


Subject(s)
Mutation/genetics , Nerve Tissue Proteins/genetics , Nerve Tissue Proteins/metabolism , Neuromuscular Junction Diseases/metabolism , Neuromuscular Junction/metabolism , Schwann Cells/metabolism , Sodium Channels/genetics , Sodium Channels/metabolism , Animals , Ankyrins/metabolism , Disease Models, Animal , Fluorescent Antibody Technique , Glial Fibrillary Acidic Protein/metabolism , In Situ Hybridization, Fluorescence , Membrane Glycoproteins/metabolism , Mice , Mice, Neurologic Mutants , Microscopy, Confocal , Motor Neurons/metabolism , Motor Neurons/ultrastructure , NAV1.2 Voltage-Gated Sodium Channel , NAV1.6 Voltage-Gated Sodium Channel , Neuromuscular Junction/genetics , Neuromuscular Junction/physiopathology , Neuromuscular Junction Diseases/genetics , Neuromuscular Junction Diseases/physiopathology , Phenotype , Rats , S100 Proteins/metabolism , Synaptic Membranes/metabolism , Synaptic Membranes/ultrastructure , Synaptic Transmission/genetics
20.
Muscle Nerve ; 33(1): 104-12, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16247767

ABSTRACT

Hypoxia impairs neuromuscular transmission in the rat diaphragm. In previous studies, we have shown that nitric oxide (NO) plays a role in force modulation of the diaphragm under hypoxic conditions. The role of NO, a neurotransmitter, on neurotransmission in skeletal muscle under hypoxic conditions is unknown. The effects of the NO synthase (NOS) inhibitor nomega-nitro-L-arginine (L-NNA, 1 mM) and the NO donor spermine NONOate (Sp-NO, 1 mM) were evaluated on neurotransmission failure during nonfatiguing and fatiguing contractions of the rat diaphragm under hypoxic (PO2 approximately 5.8 kPa) and hyperoxic conditions (PO2 approximately 64.0 kPa). Hypoxia impaired force generated by both muscle stimulation at 40 HZ (P40M) and by nerve stimulation at 40 HZ (P40N). The effect of hypoxia in the latter was more pronounced. L-NNA increased P40N whereas Sp-NO decreased P40N during hypoxia. In contrast, neither L-NNA nor Sp-NO affected P40N during hyperoxia. L-NNA only slightly reduced neurotransmission failure during fatiguing contractions under hyperoxic conditions. Consequently, neurotransmission failure assessed by comparing force loss during repetitive nerve simulation and superimposed direct muscle stimulation was more pronounced in hypoxia, which was alleviated by L-NNA and aggravated by Sp-NO. These data provide insight in the underlying mechanisms of hypoxia-induced neurotransmission failure. This is important as respiratory muscle failure may result from hypoxia in vivo.


Subject(s)
Diaphragm/innervation , Hypoxia/physiopathology , Neuromuscular Junction Diseases/physiopathology , Nitric Oxide/metabolism , Animals , Diaphragm/drug effects , Diaphragm/metabolism , Enzyme Inhibitors/pharmacology , Hypoxia/complications , Hypoxia/metabolism , Male , Muscle Contraction , Muscle Fatigue , Neuromuscular Junction Diseases/etiology , Neuromuscular Junction Diseases/metabolism , Nitric Oxide Donors/pharmacology , Nitric Oxide Synthase/antagonists & inhibitors , Nitroarginine/pharmacology , Nitrogen Oxides/pharmacology , Rats , Rats, Wistar , Spermine/analogs & derivatives , Spermine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...